Chandler Park: SunRise-1 study ESMO24 update

Chandler Park shared a post on X:

“SunRise-1 study ESMO24 update.

TAR-200 +/- cetrelimab in patients with BCG-unresponsive high risk nonmuscle bladder cancer 83.5% CR in TAR-200 arm.

Great honor to be PI in Kentucky w/Dr. Ryan Malone on this pivotal study.”

Source: Chandler Park/X 

Chandler Park, MD, FACP is an haematologist oncologist, medical journalist, and clinical researcher. He is the Advisory Dean and Clinical Professor at University of Louisville School of Medicine. He is the Kentucky Physician Representative of the ASCO State Executive Council. He is also the Medical Oncology Board Examiner at  American Board of Internal Medicine.